{"id":"iptp-dihydroartemisinin-piperaquine-plus-metronidazole","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Metallic taste (metronidazole)"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dihydroartemisinin-piperaquine is an artemisinin-based combination therapy that kills malaria parasites through multiple mechanisms including generation of reactive oxygen species and inhibition of parasite protein synthesis. Metronidazole is a nitroimidazole that generates cytotoxic free radicals to eliminate anaerobic bacteria and certain protozoa. Together, this combination aims to prevent malaria and associated infections during pregnancy (IPTp = Intermittent Preventive Therapy in pregnancy).","oneSentence":"This combination drug uses dihydroartemisinin-piperaquine to treat malaria parasites and metronidazole to treat bacterial and protozoal infections, administered as intermittent preventive therapy in pregnancy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:04.143Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Intermittent preventive therapy in pregnancy (IPTp) for malaria prevention in pregnant women in malaria-endemic regions"},{"name":"Prevention of malaria and associated infections during pregnancy"}]},"trialDetails":[{"nctId":"NCT04189744","phase":"PHASE3","title":"The ASPIRE Trial - Aiming for Safe Pregnancies by Reducing Malaria and Infections of the Reproductive Tract","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2019-12-15","conditions":"Pregnancy Malaria, Bacterial Vaginoses, Trichomonas Vaginitis","enrollment":5436}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Flagyl","D-ARTEPP®"],"phase":"phase_3","status":"active","brandName":"IPTp-dihydroartemisinin-piperaquine plus metronidazole","genericName":"IPTp-dihydroartemisinin-piperaquine plus metronidazole","companyName":"London School of Hygiene and Tropical Medicine","companyId":"london-school-of-hygiene-and-tropical-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination drug uses dihydroartemisinin-piperaquine to treat malaria parasites and metronidazole to treat bacterial and protozoal infections, administered as intermittent preventive therapy in pregnancy. Used for Intermittent preventive therapy in pregnancy (IPTp) for malaria prevention in pregnant women in malaria-endemic regions, Prevention of malaria and associated infections during pregnancy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}